Kimberly Moran, PhD, MBA

I drive strategic growth and patient-centered innovation in biopharma, combining digital transformation with boardroom insights to elevate healthcare impact and business value. As a global biopharma executive and board advisor, I bring over two decades of expertise in strategically positioning organizations for growth, enhancing operational efficiencies, and driving digital and patient-centric innovation. With a proven record in launching successful therapies in rare disease and epilepsy, I align scientific rigor, business acumen, and market insight to create value in complex, highly regulated healthcare environments. My career with UCB, a leading global biopharma company, reflects a relentless commitment to driving impactful change and delivering tangible results. In my role as SVP/Head of Rare Disease at UCB, I lead the commercial organization in transforming our rare disease unit to achieve sales projections. Under my leadership, we designed a novel “Integrated Launch Room” strategy that enabled real-time data analysis and agile decision-making – allowing us to continually improve launch effectiveness while remaining closely attuned to patient needs. My hands-on approach extends to building high-performing teams and fostering psychologically safe cultures where innovation thrives. I am recognized for pioneering UCB’s Digital Business Transformation, implementing AI-driven patient models and creating a robust data warehouse to optimize cross-functional collaboration. Additionally, my work in neurology led to the most extensive ethnography program in epilepsy, capturing patient insights that have shaped meaningful, patient-first healthcare solutions. These initiatives reflect my commitment to bridging medical advancement and commercial success while focusing deeply on the patient. As an advisor on multiple boards, I guide high-growth companies like Nile AI and INNATE in navigating the biopharma landscape, particularly in market expansion, funding strategies, and scaling operations. I offer valuable perspectives on developing innovative health tech solutions that respond to actual patient needs. I am excited to bring my strategic leadership, patient-centered vision, and commitment to growth and innovation to additional board opportunities. If you are seeking a board advisor with deep expertise in biopharmaceuticals, digital health, and market expansion, I welcome the chance to connect. #P&L #RevenueGrowth #Strategy #Digitaltransformation #Pharmaceuticalindustry #Leadership #Raredisease #Neuroscience #Diversityequityinclusion #Pharma #Biotech